

Grünenthal expands its network through Innovation Hub in Boston

Aachen, Germany and Boston, USA / 29 January 2020 – Grünenthal announced today that it has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with leading scientists and institutions. With its Innovation Hubs, Grünenthal strives to establish centres of excellence for pain research, aiming to identify and develop promising external innovation opportunities in the therapeutic area of pain. By collaborating with institutions in the Boston area – from entrepreneurial scientists to successful spin-outs and startups – Grünenthal aims to contribute its pain expertise and end-to-end R&D capabilities to help address the unmet medical needs of patients and move closer to its vision of a world free of pain. Implementing the Boston Innovation Hub is part of Grünenthal’s strategic realignment that aims to further internationalise its research activities and create more flexible structures. This scientific site will complement and strengthen the company’s footprint in the US.

Grünenthal pursues a diligent therapeutic area strategy, including peripheral neuropathic pain (PNP), chronic postoperative pain, chronic low back pain and osteoarthritis by drawing from a wide range of therapeutic modalities to deliver meaningful solutions for patients. The Innovation Hub will contribute to executing the company’s strategy, with a team of high-profile scientists and medical doctors who will operate virtually. This team will initiate, onboard and drive projects from target identification through to clinical Proof of Concept by leveraging Grünenthal’s R&D capabilities at its headquarters in Aachen as well as by collaborating with external partners.

“We’re thrilled to now have a permanent presence in Boston and offer the scientific community our expertise in pain R&D as well as our end-to-end capabilities in pharmaceutical development,” said Gabriel Baertschi, Grünenthal CEO. “I invite the scientists dedicated to addressing areas of high unmet medical need in pain to team up with us as we are working towards our vision of a world free of pain.”

“Grünenthal is committed to entering into strategic R&D partnerships and strives to bring innovative solutions to patients with high unmet medical needs,” said Jan Adams, Grünenthal CSO. “Greater Boston is recognised as the biggest biotech hub in the world and offers a unique environment for innovation. Strengthening our network and connecting closely with scientific hotspots is a crucial step in executing our strategy and enables us to build an R&D pipeline of highly innovative assets from the forefront of science.”

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focussing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2018, Grünenthal employed around 4,900 people and achieved sales of € 1.3 bn.

GRÜNENTHAL

Press Release



More information: www.grunenthal.com

Follow us on:

LinkedIn: [Grünenthal Group](#)

Twitter: [@grunenthalgroup](#)

Instagram: [grunenthal](#)

For further information please contact:

Štěpán Kráčala, Head Global Communications

Phone: +49 241 569-1335, Stepan.Kracala@grunenthal.com

Grünenthal GmbH, 52099 Aachen, Germany

###